{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-25-000109","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.257319+00:00","generated_at":"2026-05-17T03:55:19.911781+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcus Bio's EDGE-Gastric Ph2 shows median OS 26.7 months; ORR 59%","bullets":["Median OS 26.7 months (90% CI: 18.4, NE) for all patients (n=41); PD-L1 high subgroup NE.","Confirmed ORR 59% (24/41) per RECIST v1.1; 62% in PD-L1 positive and 69% in PD-L1 high subgroups.","Median PFS 12.9 months overall; 24-month OS rate 50.2% and PFS rate 25.9%.","Median follow-up 26.4 months; median time on domvanalimab+zimberelimab+chemo was 49 weeks.","No unexpected safety signals; immune-mediated TEAEs in 22% of patients, infusions reactions in 7%."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-25-000109","json":"https://secwatch.observer/filing/0001724521-25-000109.json","markdown":"https://secwatch.observer/filing/0001724521-25-000109.md","text":"https://secwatch.observer/filing/0001724521-25-000109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000109/0001724521-25-000109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000109/rcus-20251012.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:55:19.911781+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}